Cancer Registry Software Market Size, Share, and Trends 2025 to 2034

Cancer Registry Software Market Size and Forecast 2025 to 2034

The global cancer registry software market size was estimated at USD 84.16 million in 2024 and is anticipated to reach around USD 273.29 million by 2034, expanding at a CAGR of 12.50% from 2025 to 2034.

Cancer Registry Software Market Key Takeaways

• North America dominated the cancer registry software market with the largest market share of 43.87% in 2024.
• Asia Pacific is expected to expand at a double digit CAGR of 14.5% during the forecast period. 
• By deployment model, the on-premise segment accounted for the highest market share of 60% in 2024.
• By deployment model, the cloud-based segment is projected to grow at a solid CAGR of 13.2% during the forecast period.
• By component, the commercial segment has held the biggest market share of 76% in 2024 
• By component, the public segment is registering a remarkable CAGR of 13.54% during the forecast period.
• By End-use, the government & third-party segment contributed the maximum market share of 28% in 2024 
• By End-use, the research institutes segment is projected to grow at a solid CAGR of 13.24% during the forecast period.

Impact of Artificial Intelligence (AI) on Cancer Registry Software 

Using artificial intelligence (AI) techniques to process, enhance and integrate cancer registry data to make oncology and research security easier than ever. The relative advantages of AI over traditional methods. The traditional cancer registry process is time-consuming and prone to human error. The AI cancer registry automation module revolutionizes registry operations with a seamless end-to-end solution that automates data collection, analysis and reporting. 

• For Instance, August 2024, Azra AI, a leading healthcare technology company that uses artificial intelligence (AI) and automation to improve cancer diagnosis and treatment, announced its partnership with Registry Partners, a leader in medical record registration and management services. The collaboration aims to transform oncology data management and optimize the cancer registry by combining technology with professional services.

U.S. Cancer Registry Software Market Size and Growth 2025 to 2034

The U.S. cancer registry software market size was evaluated at USD 30.64 million in 2024 and is predicted to be worth around USD 100.22 million by 2034, rising at a CAGR of 12.58% from 2025 to 2034. 

North America dominated the cancer registry software market with the largest market share of 43.87% in 2024. The U.S. dominated the cancer registry software market in North America region. The North America region has presence of major market players operating in the cancer registry software market. The cancer registry software market in this region is growing due to the rising prevalence of cancer. In addition, due to high investments in the technology, the demand for cancer registry software is rising on a large scale in North America.

• For Instance, The National Program of Cancer Registries (NPCR) provides funding and support to centralized cancer registries and collects data on cancer cases in North America.

Asia-Pacific is expected to expand at a double digit CAGR of 14.5% during the forecast period. The government of emerging nations such as Japan and China are taking constant efforts for the development of the cancer registry software market. Moreover, the key market players are collaborating with the government agencies for the expansion of the healthcare sector. This factor is driving the growth of the cancer registry software market in Asia-Pacific region.

Cancer Registry Software Market Growth Factors

• By maintaining high data collection standards and following a changing process, cancer registries play a significant role in developing cancer research blood, treatment strategies and ultimately improving patient outcomes, which has led to the growth of the cancer registry software market.
• Cancer registries track the treatment and outcomes of cancer patients to help clinicians continuously improve the quality of care and prevent cancer in population testing, which has led to the growth of the cancer registry software market.
• Registries is important in controlling patterns in cancer diagnosis. From patient care standards to cancer incidence and mortality, these data form the basis of cancer research and clinical trials, which has led to the growth of the cancer registry software market.
• In September 2024, The Registry Plus Development group funding is primarily being used to support the NPCR-funded Central Cancer Registry and is unable to provide support for Registry Plus products to other countries, which has led to the growth of the cancer registry software market.

Market Scope

Market Dynamics

Driver

Enhanced Capabilities of Cancer Registry Software

The ability of the cancer registry to expand its processes for additional data collection, training, development, and electronic reporting drives the growth of cancer registry software market. This system is important because it supports the comparative effectiveness of research and makes the improvement of public health and research data more efficient. Cancer registries provide a census of cancer patients and enable cancer to be tracked at regional, state, and national levels. In addition, they can investigate cancer treatment patterns and evaluate public health measures to prevent cancer and improve survival, driving demand for advanced cancer treatment software solutions.

Opportunity

Advancements in Cloud-Based Cancer Registry Systems

The new cloud computing system developed by the national cancer registry program (NPCR) for the central cancer registry presents a significant opportunity in the cancer registry software market. This development, currently being, allows for increased collection, aggregation, and storage of cancer data. With real-time data access, the Central Cancer Registry can quickly access and analyze cancer data, allowing for faster submission of data to the CDC. Automating activities in the system will increase the accuracy, completeness, and timeliness of information. Additionally, the potential for collaboration between NPCR and other organizations to develop additional capabilities creates additional opportunities for innovation and growth in the cancer registry software market.

Restraints

Challenges in Cancer Registry Data Management and Compliance

Many healthcare organizations face significant challenges in managing timely referrals and cancer follow-up, particularly due to limited access to oncology data specialist certified (ODS-C). Additionally, fragmentation of cancer data across multiple systems and aggregation in medical records due to manual and EMR access impacts data management. Additionally, not every organization needs a complete solution, as each organization has unique needs, and changes may impact their needs over time. These factors have limited the growth of the cancer registry software market as they hinder the integration and development of software solutions.

Software Insights

The standalone segment dominated the cancer registry software market in 2024. The standalone cancer registry software is integrated with latest and advanced features. It is also easy to use and operate. The standalone cancer registry software also helps in the reduction of overhead costs. Thus, all of these factors are propelling the growth of the segment.

The integrated segment is expected to witness strong growth during the forecast period. The integrated cancer registry software helps to collaborate with the hospitals’ software. This software helps to locate patients in any location. The integrated cancer registry software also assists to track and monitor the health of patients.

Deployment Model Insights

The on-premise segment accounted for the highest market share of 60% in 2024. The on-premise cancer registry software is mostly adopted by research institutes who are doing research on cancer. The on-premise cancer registry software is embedded with advanced features which help to store data easily. The on-premise cancer registry software is less risky as compared to other types of models. Thus, the on-premise cancer registry software is widely used in hospitals and research centers.

The cloud-based segment is projected to grow at a solid CAGR of 13.2% during the forecast period. The cloud-based cancer registry software can be integrated with the real time data and standard guidelines. This software helps in the reduction of information technology overhead costs. In addition, the cloud-based cancer registry software is efficient in nature, which is driving the growth of the segment.

Component Insights

The commercial segment has held the biggest market share of 76% in 2024. The data stored in the commercial database is quite safe as compared to public database. The data stored in the commercial database can be easily tracked. The commercial database can be used across research centers and government agencies. Thus, the commercial segment is rising at a rapid pace.

The public segment is registering a remarkable CAGR of 13.54% during the forecast period. The public database is used for the various cancer research programs. The utilization of public database is growing due to the growing number of research centers all over the globe. The public database can help to track patient data from any corner of the world.

End Use Insights

The government & third-party segment contributed the maximum market share of 28% in 2024. The government of established and emerging nations is adopting cancer registry software on the large scale. This software helps to track and monitor cancer patients in their respective region. In addition, the investments made by government for the implementation of cancer registry software in hospitals. This factor is boosting the growth of the global cancer registry software market over the forecast period. 

The research institutes segment is projected to grow at a solid CAGR of 13.24% during the forecast period. The cancer registry software is widely used in research institutes due to growing prevalence of cancer. The growing research and development initiatives by biotechnology and pharmaceutical industry players are also driving the growth of the global cancer registry software market.

Cancer Registry Software Market Companies

• Rocky Mountain Cancer Data Systems
• McKesson Corporation
• Onco Inc.
• Elekta AB
• IBM Corporation
• C/Net Solutions
• Ordinal Data Inc.
• Himagine Solutions Inc.
• Electronic Registry Systems Inc.
• CONDUENT Inc.

Recent Developments

• In November 2023, ONCO, Inc., a market leader in cancer registries and services, partnered with Oncora Healthcare, a new oncology startup, to advance data-driven cancer research, analytics, and public health reporting.
• In February 2024, CooperSurgical and Fulgent Genetics, Inc. a global leader in fertility and women’s health, are collaborating to deliver a family-specific genetic screening program for the Cord Blood Registry (CBR). 
• In November 2023, Outcome Capital, a life sciences research and investment banking firm, announced the acquisition of Electronic Registry Systems, Inc. (ERS), a leader in cancer care, compliance and education services, has been acquired by Health Catalyst, Inc. Consumers, including 110 million patients. Outcome Capital is serving as the exclusive and financial advisor to ERS

Segments Covered in the Report

By Software

• Cross disciplinary
• Specific

By Deployment Model

• On-premise
• Cloud-based

By Component

• Commercial
• Public

By End Use

• Government and third party
• Private payers
• Hospital and medical practice
• Pharma biotech and medical device companies
• Research institutes

By Functionality

• Cancer Reporting to Meet State & Federal Regulations
• Patient Care Management
• Product Outcome Evaluation
• Medical Research and Clinical Studies

By Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Malaysia
• Philippines
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of the Middle East & Africa